Drug Trial Radar · NCT01098487
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Last checked: Nov 20, 2026Latest source record: Mar 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
167
Actual
Start
May 2010
Primary completion
May 2014
Study completion May 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 2, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.
Conditions
- Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag olamineDrug
Thrombopoietin receptor agonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at BaselineTime frame: Baseline
- Number of Participants With a Positive or Negative Collagen Level at BaselineTime frame: Baseline
- Number of Participants With Indicated Grade Change From Baseline in the EC Grading Scale at 1 YearTime frame: Baseline and 1 year
- Number of Participants With Indicated Change From Baseline in the EC Grading Scale at 2 YearsTime frame: Baseline and 2 years
- Number of Participants With a Positive or Negative Collagen Level at 1 YearTime frame: 1 year
- Number of Participants With a Positive or Negative Collagen Level at 2 YearTime frame: 2 years
Locations
34 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
New York, New York
GSK Investigational Site
Hradec Králové, Czechia
GSK Investigational Site
Olomouc, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Caen, France
GSK Investigational Site
Créteil, France
GSK Investigational Site
Pessac, France
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Düsseldorf, North Rhine-Westphalia, Germany
GSK Investigational Site
Düsseldorf, North Rhine-Westphalia, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Shatin, New Territories, Hong Kong
GSK Investigational Site
Debrecen, Hungary
GSK Investigational Site
Győr, Hungary
GSK Investigational Site
Szeged, Hungary
GSK Investigational Site
Ludhiana, India
GSK Investigational Site
Pune, India
GSK Investigational Site
Surat, India
GSK Investigational Site
Vellore, India
GSK Investigational Site
Bologna, Emilia-Romagna, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Padova, Veneto, Italy
GSK Investigational Site
Vicenza, Veneto, Italy
GSK Investigational Site
Karachi, Pakistan
GSK Investigational Site
Lahore, Pakistan
GSK Investigational Site
Moscow, Russia
GSK Investigational Site
Novosibirsk, Russia
GSK Investigational Site
Saint Petersburg, Russia
GSK Investigational Site
Seongnam-si Gyeonggi-do, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.